The market for injectable products has evolved quite markedly over the last few years and this rate of change continues apace with new biologic drugs and drug delivery systems being developed and brought to the market. What does this mean for drug administration devices such as syringes, autoinjectors and bolus delivery systems?
The answer quite simply is greater variety. Device requirements will vary quite considerably from: drug to drug; patient group to patient group; region to region and brand to brand.
Our feedback from the market suggests that a couple of the key challenges to be considered are the need for devices capable of administering more viscous materials and/or delivering increased volumes. In addressing this issue the market is focused on two alternatives: the 2.25 ml auto injector or 'stick on' bolus delivery systems. Is it possible to introduce devices that will provide alternatives to current offerings that will prove to be more appealing to different patient profiles and allow different types of drug to be successfully administered?
In discussions with pharmaceutical companies there are a set of characteristics that they would like to see in an injection system. A single platform technology which could flexibly be applied across a whole range of drugs appears to be desirable rather than a standard 'off the shelf' device. Whilst the core technology should ideally be similar, the embodiment and functionality will be targeted to meet the specific patient needs and drug characteristics. Additionally, within the device range companies would like the platform to be capable of delivering variable dose volumes including larger volumes and higher viscosity fluids. As well as addressing these challenges there is also an increasing desire to minimise syringe breakage, a significant issue with many of today's systems. Join this webinar to find out more about the latest challenges within injectable drug administration, and how and why they are being addressed. You will learn about the opportunities available for drugs with an injectable profile and what options are available to cater for a wide range of patient demographic.
This webinar will discuss:
- Our findings on research conducted from a pharma company and patient centric analysis of the autoinjector market.
- A discussion of the limitations and alternatives to the current "spring" mechanism within delivery devices.
- The benefits and flexibilities afforded through the use of liquefied gas as a delivery medium.
- The innovation of the Syrina and Vapoursoft technologies to address these current challenges.
Ian Anderson,
Innovation Director
Ian Anderson has over 26 years' experience developing innovative new products in a diverse array of industries from aerospace and consumer products through to medical devices. Ian joined Bespak 4 and half years ago, after a spell of 14 years in technology consultancy at The Technology Partnership (TTP) followed by Sagentia where he headed up the development team. Prior to consultancy he worked in the aeronautical (Thales), broadcast (Vitec) and laboratory (Thermo) industries. He joined Bespak to set up Bespak's Cambridge Innovation Centre and use his experience to diversify the business through the creation of the next generation of drug mixing and administration devices based on patient needs. Ian has a MEng in Engineering and a MSc in innovative design from Cranfield University.
Andrew Donnelly,
Innovation Manager
Andy Donnelly, Ph.D. has over 18 years of experience working within the field of parenteral science and joined Bespak's Innovation Group in September 2013 as an Innovation Manager, helping to develop next generation delivery devices to meet the ever increasing requirements of the pharmaceutical and biotech industry. Previously Andy was based in the USA where he established and subsequently led MedImmune's drug delivery and device development group, responsible for evaluation and development of innovative device and formulation drug delivery technologies. Prior to this Andy spent over 12 years working in AstraZeneca's formulation development groups in both Sweden and the UK, work which included both small and large molecules. Andy has a degree in Pharmacy and a Ph.D. in drug delivery from the Welsh School of Pharmacy, UK.
- To gain a basic understanding of the injectable drug delivery market trends
- Consider ways to ensure your platform matches the requirements of your portfolio and allows freedom to formulate
- Understand the potential for the use of simple devices to assist blinding in clinical trials
- Gain a basic understanding of the flexibility of Bespak’s injection systems
- Heads of Device Development
- Fellows/principal Scientists
- Director of Device Development
- Director New Technologies
- Device Engineers
- Drug Delivery Scientists
- Mechanical Engineers
- Manager Device Development
- Heads of pharmaceutical development
- Heads of product development
- Pharmaceutical Scientists
- Project Managers
- Product Managers
- Heads of Marketing
